HIV infection and bone disease
1Dept of Medicine, Cambridge Biomedical Campus Francis Crick Ave, Cambridge CB2 0SL, UK. jec1001@cam.ac.uk.
Insights
Antiretroviral therapy improves HIV survival but increases fracture risk due to bone loss, especially early in treatment. Bone health assessment and interventions are crucial for aging HIV patients.
Area of Science:
- Gerontology
- Infectious Diseases
- Bone Metabolism
Background:
- Antiretroviral therapy (ART) has transformed Human Immunodeficiency Virus (HIV) infection into a manageable chronic condition, increasing life expectancy.
- An aging HIV-infected population experiences a rise in non-AIDS comorbidities, notably osteoporosis and elevated fracture risk.
- Fracture pathogenesis in HIV is complex, influenced by traditional factors and HIV-specific elements.
Purpose of the Study:
- To highlight the emergence of osteoporosis and fracture risk in the aging HIV-infected population.
- To discuss the multifactorial causes of fractures in individuals with HIV.
- To recommend strategies for managing bone health in HIV patients.
Main Methods:
- Review of current literature on HIV, aging, bone metabolism, and fracture risk.
- Analysis of the impact of ART initiation and long-term use on bone mineral density.
- Evaluation of risk factors contributing to fractures in HIV-infected individuals.
Main Results:
- Significant bone loss is observed upon initiating ART, which tends to stabilize with long-term treatment.
- HIV-associated osteoporosis and increased fracture risk are recognized comorbidities in the aging HIV population.
- Fracture risk is multifactorial, involving both general and HIV-specific risk factors.
Conclusions:
- Fracture risk assessment and bone mineral density measurement are recommended for HIV-infected individuals.
- Lifestyle modifications to promote bone health should be advised.
- Bisphosphonate therapy should be considered for HIV patients at high risk of fracture.
Abstract:
The success of antiretroviral therapy in treating HIV infection has greatly prolonged life expectancy in affected individuals, transforming the disease into a chronic condition. A number of HIV-associated non-AIDS comorbidities have emerged in the ageing HIV-infected population, including osteoporosis and increased risk of fracture. The pathogenesis of fracture is multifactorial with contributions from both traditional and HIV-specific risk factors. Significant bone loss occurs on initiation of antiretroviral therapy but stabilizes on long-term therapy. Fracture risk assessment should be performed in HIV-infected individuals and bone mineral density measured when indicated. Lifestyle measures to optimize bone health should be advised and, in individuals at high risk of fracture, treatment with bisphosphonates considered.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Sexually Transmitted Infections
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Bone Remodeling


